The JUND Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HT29 human colorectal adenocarcinoma cells, with targeted disruption of the JUND gene. This product provides a loss-of-function model for studying AP-1 transcription factor subunit JUND in a colorectal cancer context. As a polyclonal pool, it retains the genetic heterogeneity of the parental population, enabling robust functional studies without clonal bias.
The HT29 cell line was established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female and is widely used as a model for intestinal epithelial biology and colorectal cancer. These adherent epithelial cells exhibit intermediate differentiation features, making them suitable for investigating tumor signaling, proliferation, and drug responses in an oncogenic background.
JUND encodes a component of the AP-1 transcription factor complex, which forms dimers with c-JUN, c-FOS, and ATF family members. JUND is activated by upstream kinases ERK1/2, JNK, and p38, which respond to stimuli such as EGF, TGF-alpha, and IL-6. Active JUND-containing complexes regulate transcription of targets involved in cell cycle (CCND1, CDKN1A), apoptosis (BCL2L1), angiogenesis (VEGFA), and inflammation (MMP9, IL8). JUND also interacts with co-regulators p300/CBP, HDAC1, and BACH1, which modulate its activity. The transcription factor participates in crosstalk with Wnt/??-catenin, NF-??B, and STAT3 pathways, contributing to context-dependent tumor-suppressive or oncogenic functions.
In HT29 colorectal adenocarcinoma cells, JUND knockout disrupts a key regulatory node, allowing dissection of AP-1 network contributions to tumor biology. This model is particularly relevant for studying how JUND influences proliferation and survival through effectors like CCND1 and BCL2L1, and for investigating its role in inflammatory signaling via IL-8 and MMP9. The polyclonal nature of the knockout minimizes clonal artifacts, providing a reliable system to analyze JUND??s dual functions in a malignant colorectal epithelium.
Applications include western blotting and RT-qPCR for target protein and gene analysis, ChIP-qPCR for AP-1 binding site occupancy, and functional assays such as MTT-based proliferation, Annexin V apoptosis, and migration/invasion studies. The cells are suited for drug sensitivity profiling, AP-1 luciferase reporter assays, and transcriptomic analysis via RNA-seq. For further information, please contact Ascent Research.
